AHA, Others Urge Congress to Reauthorize Health Care Preparedness Law

The Honorable Charles Schumer Majority Leader US Senate S-221 Capitol Building Washington, DC 20510 The Honorable Mitch McConnell Minority Leader US Senate S-230 Capitol Building Washington, DC 20510

The Honorable Mike Johnson Speaker of the House US House of Representatives H-232 Capitol Building Washington, DC 20515

The Honorable Hakeem Jeffries Minority Leader US House of Representatives H-204 Capitol Building Washington, DC 20515

Re: The Urgent Need to Reauthorize PAHPA

Dear Leaders Schumer and McConnell, Speaker Johnson, and Leader Jeffries,

On behalf of the undersigned organizations, we write to express our strong desire to see the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorized before the end of the calendar year in the same bipartisan fashion it has been supported since the original authorization 17 years ago.

As you know, PAHPA underpins Department of Health and Human Services (HHS) agencies, programs, and funding authorizations for addressing national health security threats. PAHPA created the HHS Assistant Secretary for Preparedness and Response (now the Administration for Strategic Preparedness and Response) and the Biomedical Advanced Research and Development Authority (BARDA) and provides important congressional oversight and direction to federal programs related to early warning, prevention, preparedness, and response.

This overall framework expired on September 30, 2023, requiring stopgap, temporary extensions in the continuing resolution, which expires on November 17. We encourage Congress to include a comprehensive five-year PAHPA reauthorization in the next moving legislative vehicle.

The last three PAHPA bills all shared major recurring themes: they all adjusted to the changing threat landscape, focused on challenges identified since the prior bill, and considerably strengthened our nation’s health security with each reauthorization.

Our nation’s changing health security threat landscape and the federal government’s responsibility to protect the American people demand that we work together now to find a strong bipartisan path forward to reauthorize this critical legislation. Whether the next health security threat is naturally occurring, the result of an accident, or intentionally caused, our country must be in a better position to prevent, prepare for, and respond to such incidents.

Failing to reauthorize PAHPA would have serious effects on our country’s economic wellbeing, national security, and health security given the rapidly changing threat landscape.

We are hopeful that PAHPA will remain a strong bipartisan legislative framework, as it has always been. We stand ready to assist you in whatever ways we can to help get this important law reauthorized this year.

Sincerely (in alphabetical order),

1Day Sooner
Acadian Ambulance Service, Inc.
Adaptive Phage Therapeutics
Aequor Inc.
American Ambulance Association
America’s Essential Hospitals
American College of Emergency Physicians
American College of Surgeons
American Hospital Association
American Lung Association
American Pharmacies
American Public Health Association
American Society for Microbiology
Arizona Bioindustry Association, Inc. (AZBio)
Association for Professionals in Infection
Control and Epidemiology
Association of Maternal & Child Health
Programs
Association of State and Territorial Health
Officials
Asthma and Allergy Foundation of America
AstraZeneca Pharmaceuticals
ATCC (American Type Culture Collection)
Atea Pharmaceuticals, Inc.
Bavarian Nordic
Big Cities Health Coalition
BioCT
Healthcare Leadership Council
Healthcare Ready
Helix
HIMSS (Healthcare Information and Management Systems Society)
HIV Medicine Association
IAVI (International AIDS Vaccine Initiative)
Illinois Biotechnology Innovation
Organization
Infectious Diseases Society of America
INOVIO Pharmaceuticals
Institute for Progress
Johns Hopkins Center for Health Security
Life Sciences PA
Locus Biosciences
Mallinckrodt
Marked By Covid
MassBio
McKesson
Medical Alley
Medical Countermeasures Coalition
Missouri Biotechnology Association (MOBIO)
National Association of County and City
Health Officials
National Immigration Law Center
New Mexico Biotechnoiogy & Biomedical
Association (NMBio)
New Orleans BioInnovation Center
NewYorkBIO
NightHawk Biosciences
 
BioForward Wisconsin
BioKansas
BioNJ
Biotechnology Innovation Organization (BIO)
Bugworks
Cencora
Colorado BioScience Association
Council of State and Territorial
Epidemiologists
Council of State Bioscience Associations (CSBA)
CSL Seqirus
Emergency Department Practice
Management Association
Emergent BioSolutions
Federation of American Scientists
FluGen Inc.
Georgia Bio
Gerontological Society of America
Ginkgo Bioworks
Global Health Investment Corporation
Global Health Technologies Coalition
Gryphon Scientific
GSK
Health Industry Distributors Association (HIDA)
Healthcare Distribution Alliance
Novavax
Ochsner Health
Ohio Life Sciences Association
Oklahoma Bioscience Association
PDS Biotechnology
PharmaJet Inc.
Premier Inc.
Public Health Accreditation Board
Research!America
SAB Biotherapeutics, Inc.
Sanofi
SecureBio
Shionogi Inc.
SIGA Technologies, Inc.
Society for Public Health Education
Soligenix, Inc.
Technologies for Pandemic Defense
Texas Healthcare & Bioscience Institute
Tonix Pharmaceuticals
Trinity Health
TrippBio, Inc.
Trust for America’s Health
United States Pharmacopeia (USP)
University of Hawaii
University of Maryland School of Medicine
Valneva USA
Vaxxas Inc
Virginia Biotechnology Association

cc:

Chair Bernie Sanders
Health, Education, Labor & Pensions Committee
US Senate
Chair Cathy McMorris Rodgers
Energy & Commerce Committee
US House of Representatives

Ranking Member Bill Cassidy
Health, Education, Labor & Pensions Committee
US Senate

Ranking Member Frank Pallone
Energy & Commerce Committee
US House of Representatives